


, and

B²
contREMARKS

Claims 1-21 are pending in the present application, of which claim 21 is new and claims 2-20 have been withdrawn from further consideration pursuant to 35 USC 121. Accordingly, claims 1 and 21 are currently under consideration.

Claim 1 has been amended to more clearly define that which Applicant regards as his invention. In particular, claim 1 has been amended to recite that R_1 is not an ω -1 alcohol substituted $C_{(1-8)}$ alkyl when both X and Y are $N(R_3)$, Z is $C(R_3)$ and R_3 is H or $C_{(1-3)}$ alkyl. Adequate support for the amendment should be apparent throughout the detailed specification including the extensive number of examples provided by Applicant in the tables and examples. Accordingly, it is respectfully submitted that no new matter has been added by this Amendment.

Claim 21 is new and is fully supported by original claim 8. Further, it is respectfully submitted that new claim 21 falls within the elected species and should be considered together with claim 1. Accordingly, consideration of new claim 21 together with claim 1 is respectfully solicited.

Claim 1 was rejected under 35 USC 103 as being unpatentable over Hinze et al. (U.S. 4,515,795). The rejection is traversed and it is respectfully submitted that claims 1 and 21 now in the application are patentable within the meaning of 35 USC 103.

Hinze et al. relate to xanthine compounds having ω -1 alcohol substituents. It is respectfully submitted that claim 1 is patentably distinguishable over Hinze et al. and that claim 21 is also free of the teaching of Hinze et al. Accordingly, reconsideration and withdrawal of the rejection are respectfully solicited.


Applicant respectfully submits that by the present Amendment, the rejected claim is in better form for consideration on appeal and that the issues before the Examiner have been materially reduced. Accordingly, entry of the present Amendment and remarks, and favorable consideration, are respectfully solicited pursuant to 37 CFR 1.116.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings to Show Changes Made."

To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Daniel Bucca, Ph.D.
Registration No. 42,368

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 DB:ajb
Date: April 6, 2001
Facsimile: (202) 756-8087

Version With Markings to Show Changes Made

Claim 1 has been amended as follows:

1. (Twice Amended) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula:



wherein:

X, Y and Z are independently selected from a member of the group consisting of C(R₃),

N, N(R₃) and S;

R₁ is selected from a member of the group consisting of hydrogen, methyl, C₍₅₋₉₎alkyl, C₍₅₋₉₎alkenyl, C₍₅₋₉₎alkynyl, C₍₅₋₉₎hydroxyalkyl, C₍₃₋₈₎alkoxyl, C₍₅₋₉₎alkoxyalkyl, the R₁ being optionally substituted;

R₂ and R₃ are independently selected from a member of the group consisting of hydrogen, halo, oxo, C₍₁₋₂₀₎alkyl, C₍₁₋₂₀₎hydroxyalkyl, C₍₁₋₂₀₎thioalkyl, C₍₁₋₂₀₎alkylamino, C₍₁₋₂₀₎alkylaminoalkyl, C₍₁₋₂₀₎aminoalkyl, C₍₁₋₂₀₎aminoalkoxyalkenyl, C₍₁₋₂₀₎aminoalkoxyalkynyl, C₍₁₋₂₀₎diaminoalkyl, C₍₁₋₂₀₎triaminoalkyl, C₍₁₋₂₀₎tetraaminoalkyl, C₍₅₋₁₅₎aminotrialkoxyamino, C₍₁₋₂₀₎alkylamido, C₍₁₋₂₀₎alkylamidoalkyl, C₍₁₋₂₀₎amidoalkyl, C₍₁₋₂₀₎acetamidoalkyl, C₍₁₋₂₀₎alkenyl, C₍₁₋₂₀₎alkynyl, C₍₃₋₈₎alkoxyl, C₍₁₋₁₁₎alkoxyalkyl, and C₍₁₋₂₀₎dialkoxyalkyl;

with the proviso that R_1 is not an ω -1 alcohol substituted $[C_{(5-8)}]$ $C_{(1-8)}$ alkyl when both X and Y are $N(R_3)$, Z is $C(R_3)$ and R_3 is H or $C_{(1-3)}$ alkyl.